Blue Blood Biotech

CompanyTaiwan

Blue Blood Biotech develops one asset, in phase 2 (BB-101 in diabetic foot ulcer). Mostly protein or enzyme; based in Taiwan.

1
Asset
Furthest stage
Phase 2
1
Trial
0
Signals

Pipeline

1
  • BB-101

    Promotes wound healing and tissue repair in diabetic ulcers.

    Phase 2, Protein or enzyme, diabetic foot ulcer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Similar companies4

Intelligence